Literature DB >> 9258577

Readying a US measure of health status, the SF-36, for use in Canada.

S W Dauphinee1, L Gauthier, B Gandek, L Magnan, U Pierre.   

Abstract

OBJECTIVE: To culturally adapt and translate for use in French- and English-speaking areas of Canada the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), a carefully developed and standardized measure that is useful for assessing the outcomes for care.
DESIGN: For the Canadian French version, the methods involved forward and backward translations, quality ratings of the translated product, a scaling exercise and pilot tests. A process of cultural adaptation, along with the scaling exercise and pilot tests, was used to create a form in Canadian English.
RESULTS: The authors produced acceptable versions of the SF-36 in Canadian French and English.
CONCLUSIONS: Although further psychometric testing of the Canadian versions of the SF-36 is desirable, they are now available for use in clinical practice and research in Canada.

Mesh:

Year:  1997        PMID: 9258577

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  19 in total

1.  The Canadian SF-36 health survey: normative data add to its value.

Authors:  S Wood-Dauphinee
Journal:  CMAJ       Date:  2000-08-08       Impact factor: 8.262

Review 2.  Quality of life in older people: a structured review of generic self-assessed health instruments.

Authors:  K L Haywood; A M Garratt; R Fitzpatrick
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

3.  Relationship between multimorbidity and health-related quality of life of patients in primary care.

Authors:  Martin Fortin; Gina Bravo; Catherine Hudon; Lise Lapointe; José Almirall; Marie-France Dubois; Alain Vanasse
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

4.  Feasibility of a Hybrid Web-Based and In-Person Self-management Intervention Aimed at Preventing Acute to Chronic Pain Transition After Major Lower Extremity Trauma (iPACT-E-Trauma): A Pilot Randomized Controlled Trial.

Authors:  M Bérubé; C Gélinas; N Feeley; G Martorella; J Côté; G Y Laflamme; D M Rouleau; M Choinière
Journal:  Pain Med       Date:  2019-10-01       Impact factor: 3.750

5.  Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group.

Authors:  W M Hopman; T Towheed; T Anastassiades; A Tenenhouse; S Poliquin; C Berger; L Joseph; J P Brown; T M Murray; J D Adachi; D A Hanley; E Papadimitropoulos
Journal:  CMAJ       Date:  2000-08-08       Impact factor: 8.262

6.  AGY, a Novel Egg Yolk-Derived Anti-gliadin Antibody, Is Safe for Patients with Celiac Disease.

Authors:  Dory A Sample; Hoon H Sunwoo; Hien Q Huynh; Heather L Rylance; Cheri L Robert; Bi-Wen Xu; Sung H Kang; Naiyana Gujral; Levinus A Dieleman
Journal:  Dig Dis Sci       Date:  2016-12-29       Impact factor: 3.199

7.  Comparing the psychometric properties of preference-based and nonpreference-based health-related quality of life in coronary heart disease. Canadian Collaborative Cardiac Assessment Group.

Authors:  L Lalonde; A E Clarke; L Joseph; T Mackenzie; S A Grover
Journal:  Qual Life Res       Date:  1999-08       Impact factor: 4.147

8.  Quality of life before and after heart valve surgery is influenced by gender and type of valve.

Authors:  Marie-Christine Taillefer; Gilles Dupuis; Jean-François Hardy; Sylvie LeMay
Journal:  Qual Life Res       Date:  2005-04       Impact factor: 4.147

9.  Feasibility and reliability of health-related quality of life measurements among tuberculosis patients.

Authors:  M J Dion; P Tousignant; J Bourbeau; D Menzies; K Schwartzman
Journal:  Qual Life Res       Date:  2004-04       Impact factor: 4.147

10.  The wait for total hip replacement in patients with osteoarthritis.

Authors:  Marie-Claire Gaudet; Debbie Ehrmann Feldman; Michel Rossignol; David Zukor; Michael Tanzer; Charles Gravel; Nicholas Newman; Réjean Dumais; Ian Shrier
Journal:  Can J Surg       Date:  2007-04       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.